Table 4 Comparison between group I and group II before and 4 h after treatment
From: Evaluation of inhaled beta-2 agonist in management of transient tachypnea of the newborn
Variable | Before treatment | P value | After treatment | P value | ||
|---|---|---|---|---|---|---|
Group I | Group II | Group I | Group II | |||
Respiratory rate (Breath/min) | 74.36 ± 8.08 | 72.11 ± 7.56 | 0.15 | 71.47 ± 8.15 | 62.59 ± 7.43 | 0.0000 |
Heart rate (Beats/min) | 148.32 ± 11.52 | 144.78 ± 10.34 | 0.06 | 146.33 ± 22.28 | 142.72 ± 10.25 | 0.056 |
TTN Score* | 7 (6–9) | 8 (7–10) | 0.01 | 7 (5–9) | 3 (3–5) | 0.0000 |
PH | 7.28 ± 0.14 | 7.26 ± 0.13 | 0.46 | 7.31 ± 0.09 | 7.36 ± 0.07 | 0.02 |
FiO2 (%)* | 65(50–75) | 65(50–80) | 0.84 | 60(45–75) | 30(25–45) | 0.0000 |
PaO2 (mmHg) | 68.04 ± 10.03 | 67.69 ± 11.19 | 0.66 | 71.58 ± 9.98 | 81.77 ± 10.84 | 0.0000 |
PaCO2 (mmHg) | 44.21 ± 6.74 | 45.48 ± 6.53 | 0.19 | 46.17 ± 6.42 | 40.33 ± 6.76 | 0.0004 |
Serum K (mEq/L) | 4.24 ± 0.68 | 4.36 ± 0.64 | 0.36 | 4.37 ± 0.71 | 4.15 ± 0.61 | 0.08 |
Glucose (mg/dl) | 79.04 ± 10.17 | 77.81 ± 10.19 | 0.31 | 77.85 ± 9.73 | 80.26 ± 9.94 | 0.21 |